ÐÓ°ÉÔ­´´

Leyden Labs, based in Amsterdam, specializes in producing medicines to safeguard against respiratory viruses. Their focus on this niche area is significant as current vaccines, masks, and antiviral treatments show limited efficacy against evolving viral threats. By potentially offering broader or more targeted protection, Leyden Labs could become a key player in the biotech and health technology sectors. Backed by major investors like GV and SoftBank Group, the company enjoys strong confidence in its business model and technological innovation. As the focus shifts from reactive to proactive measures, Leyden Labs' products could see substantial demand, solidifying their market position.